Abbvie Inc: (NYSE: ABBV)

$46.54

0.28 (0.61%)

Volume 4,705,874

May 21 04:04 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		46.17 - 46.96
	
		52wk Low - High
		32.51 - 47.34
	
		Previous Close
		46.26
	
		Avg. Volume
		5,883,799
	
		Industry
		LARGE CAP PHARMA
	
		Market Cap
		73.23 B
	
		Div - Yield
		1.60 - 3.46
	
		Beta
		-0.01
	
		PE (Forward)
		14.78
	
		Current Year Est.
		3.13
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		186 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/17/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            14.78
                        
                            PEG Ratio
                            2.25
                        
                            Current Year Est.
                            3.13
                        
                            Current Quarter Estimate
                            0.79
                        
                            Most Accurate Estimate
                            0.79
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-26-2013
                        
                            EPS Last Year
                            3.47
                        
                            Expected Earnings Growth
                            6.57%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.   
Full ABBV Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ABBV Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.79	0.77	3.13	3.24
Number of Estimates	6	5	9	7
Low Estimate	0.78	0.76	3.10	3.15
High Estimate	0.80	0.78	3.17	NA
Year Ago EPS	0.80	1.01	3.35	3.13
EPS Growth	-1.04%	-23.56%	-6.60%	3.55%

More ABBV Estimates

Average Earnings Estimates for ABBV

EPS Growth for ABBV

Industry Analysis

Name	Symbol	Previous Close
ABBVIE INC	ABBV	46.26
ABBOTT LABS	ABT	37.81
ALLERGAN INC	AGN	98.50
ASTRAZENECA PLC	AZN	51.50
BRISTOL-MYERS	BMY	43.76
GLAXOSMITHKLINE	GSK	52.21
JOHNSON & JOHNS	JNJ	88.01
LILLY ELI & CO	LLY	55.02
MERCK & CO INC	MRK	45.21
NOVARTIS AG-ADR	NVS	74.16

Sector:Medical>> Industry:LARGE CAP PHARMA

COMPARE TICKER vs. Its Peers

Zacks Commentary

JNJ's Simponi Label Expanded

May 21, 2013

Merck's Liptruzet Approved in the US

May 07, 2013

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus

May 07, 2013

Bayer Discontinues Hemophilia Study

May 06, 2013

Positive Opinion on Allergan Candidate

May 06, 2013

Good News for Bristol-Myers

May 06, 2013

Covidien Provides 2013 Outlook

May 06, 2013

Earnings Plummet, Outlook Maintained at Sanofi

May 03, 2013

More ABBV Zacks Commentary

Financials

EPS TTM	3.47
Sales	18,380
Net Income	5,360
Price/Earnings	13.33
Price/Book	24.76
Price/Cash Flow	16.24
Price/Sales	3.95

More ABBV Financials

News

AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy - Pr Newswire

May 20, 2013

AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy - Pr Newswire Europe

May 20, 2013

AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease - Pr Newswire

May 17, 2013

AbbVie receives breakthrough therapy designation from FDA for HCV regimen - Datamonitor

May 17, 2013

13F Watch: Third Point`s Fast Trades; Firm Exits Herbalife and Morgan Stanley - Benzinga

May 16, 2013

Cheerleaders: Look Beyond Pharma For Jobs - YCharts

May 16, 2013

AbbVie and Alvine announce collaboration for oral therapy for celiac disease - M2

May 15, 2013

AbbVie and Alvine announce collaboration for oral therapy for celiac disease - M2

May 15, 2013

See All News Stories on ABBV

Broker Recommendations

Current ABR	2.25
ABR (Last Week)	2.25
# of recs in ABR	10
Average Target Price	43.75
Industry Rank by ABR	186 out of 265
Rank in Industry	1 out of 15

More ABBV Broker Recommendations

Day Low - High	46.17 - 46.96
52wk Low - High	32.51 - 47.34
Previous Close	46.26
Avg. Volume	5,883,799
Industry	LARGE CAP PHARMA
Market Cap	73.23 B
Div - Yield	1.60 - 3.46
Beta	-0.01
PE (Forward)	14.78
Current Year Est.	3.13
Quarterly Earnings ESP	0.00%

PE (Forward)	14.78
PEG Ratio	2.25
Current Year Est.	3.13
Current Quarter Estimate	0.79
Most Accurate Estimate	0.79
Earnings ESP	0.00%
Next Earnings Report Date	07-26-2013
EPS Last Year	3.47
Expected Earnings Growth	6.57%

Username: Password:

Remember me [?]

Abbvie Inc: (NYSE: ABBV)

$46.54

0.28 (0.61%)

Volume 4,705,874

May 21 04:04 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:LARGE CAP PHARMA

Zacks Commentary

Financials

News

Broker Recommendations